Baxter International News

NEW YORK &#8212 Shares of some top pharmaceuticals companies were mixed at the close of trading: Baxter International Inc.

NEW YORK &#8212 Shares of some top pharmaceuticals companies are mixed at 1 p.m.: Baxter International Inc.

NEW YORK &#8212 Shares of some top pharmaceuticals companies were mixed at the close of trading: Baxter International Inc.

FOR IMMEDIATE RELEASE Media Contacts Deborah Spak, 948-2349 Investor Contacts Mary Kay Ladone, 948-3371 Clare Trachtman, 948-3085 BAXTER TO PRESENT AT THE LEERINK SWANN 2012 GLOBAL HEALTHCARE CONFERENCE DEERFIELD, Ill., February 2, 2012 - Baxter International Inc.

NEW YORK &#8212 Shares of some top pharmaceuticals companies are down at 10 a.m.: Baxter International Inc.

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved TISSEEL [Fibrin Sealant] to include general hemostasis in surgery when control of bleeding by standard surgical techniques is ineffective or impractical.

The 10-second takeaway For the quarter ended Dec. 31 , Baxter International met expectations on revenues and met expectations on earnings per share.

NEW YORK &#8212 Shares of some top pharmaceuticals companies were mixed at the close of trading: Baxter International Inc.

Baxter International 's stock had its "neutral" rating reiterated by Zacks Investment Research in a report issued on Friday.

The products developed by the company are used in the treatment of fractures, bone defects, spinal, joint surgeries and various other bone related problems.

Good morning, ladies and gentlemen, and welcome to Baxter International's Fourth Quarter Earnings Conference Call.

Baxter International Inc. reported fourth quarter and fiscal 2011 adjusted earnings per share of $1.17 and $4.31, respectively, thereby beating the corresponding Zacks Consensus Estimates of $1.16 and $4.30, and surpassing the year-ago earnings of $1.11 and $3.98, respectively.

S&P 500 component Baxter International Inc reported its results for the fourth quarter.

NEW YORK &#8212 Shares of some top pharmaceuticals companies are mixed at 1 p.m.: Baxter International Inc.

Baxter International 's stock had its "overweight" rating reiterated by equities research analysts at Morgan Stanley in a research note issued to investors on Tuesday.

A German insurer is refusing to cover Baxter International Inc.'s share of a settlement for thousands of suits brought by patients infected by tainted blood in the 1970s and '80s, exposing the Deerfield-based maker of medical products to millions of dollars in losses.

Baxter International Inc. : Dougherty is cautious ahead of Baxter's Q4 report on January 26 and believes the company could provide lower than expected 2012 guidance.

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10% [Immune Globulin Infusion ] , for the treatment of mild to moderate Alzheimer's disease.

S&P 500 component Baxter International, Inc. will unveil its latest earnings on Thursday, January 26, 2012.